Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis
European Journal of Neurology · 2023
DOI: 10.1111/ene.15706 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neurology, 2023. Verfasst von Ibrahima Diouf und 59 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, CORe, University of Melbourne, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Multiple Sclerosis, Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Relapsing-Remitting. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, Roche.
Abstract (Originalsprache)
Background and purpose This study assessed the effect of patient characteristics on the response to disease‐modifying therapy (DMT) in multiple sclerosis (MS).
Methods
We extracted data from 61,810 patients from 135 centers across 35 countries from the MSBase registry. The selection criteria were: clinically isolated syndrome or definite MS, follow‐up ≥ 1 year, and Expanded Disability Status Scale (EDSS) score ≥ 3, with ≥1 score recorded per year. Marginal structural models with interaction terms were used to compare the hazards of 12‐month confirmed worsening and improvement of disability, and the incidence of relapses between treated and untreated patients stratified by their characteristics.
Results
Among 24,344 patients with relapsing MS, those on DMTs experienced 48% reduction in relapse incidence (hazard ratio [HR] = 0.52, 95% confidence interval [CI] = 0.45–0.60), 46% lower risk of disability worsening (HR = 0.54, 95% CI = 0.41–0.71), and 32% greater chance of disability improvement (HR = 1.32, 95% CI = 1.09–1.59). The effect of DMTs on EDSS worsening and improvement and the risk of relapses was attenuated with more severe disability. The magnitude of the effect of DMT on suppressing relapses declined with higher prior relapse rate and prior cerebral magnetic resonance imaging activity. We did not find any evidence for the effect of age on the effectiveness of DMT. After inclusion of 1985 participants with progressive MS, the effect of DMT on disability mostly depended on MS phenotype, whereas its effect on relapses was driven mainly by prior relapse activity.
Conclusions
DMT is generally most effective among patients with lower disability and in relapsing MS phenotypes. There is no evidence of attenuation of the effect of DMT with age.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, CORe, University of Melbourne, Melbourne, Victoria, Australia.
- Department of Neurology, Neuroimmunology Centre, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
- Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic.
- Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Catania, Italy.
- Isfahan University of Medical Sciences, Isfahan, Iran.
- Dokuz Eylul University, Konak/Izmir, Turkey.
ORCID-Profile: Izanne Roos, Francesco Patti, Murat Terzi, Diana Ferraro, Bassem Yamout, Vincent van Pesch, Yolanda Blanco
Förderung
- National Health and Medical Research Council
- Roche
Zitieren
APA
Diouf, I., Malpas, C. B., Sharmin, S., Roos, I., Horakova, D., Havrdova, E. K., Patti, F., Shaygannejad, V., Ozakbas, S., Izquierdo, G., Eichau, S., Onofrj, M., Lugaresi, A., Alroughani, R., Prat, A., Girard, M., Duquette, P., Terzi, M., Boz, C., …, & Prevost, J. (2023). Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis. European Journal of Neurology. https://doi.org/10.1111/ene.15706
Vancouver
Diouf I, Malpas CB, Sharmin S, Roos I, Horakova D, Havrdova EK, et al. Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis. European Journal of Neurology. 2023. doi:10.1111/ene.15706
BibTeX
@article{Diouf2023,
author = {Diouf, Ibrahima and Malpas, Charles B and Sharmin, Sifat and Roos, Izanne and Horakova, Dana and Havrdova, Eva Kubala and Patti, Francesco and Shaygannejad, Vahid and Ozakbas, Serkan and Izquierdo, Guillermo and Eichau, Sara and Onofrj, Marco and Lugaresi, Alessandra and Alroughani, Raed and Prat, Alexandre and Girard, Marc and Duquette, Pierre and Terzi, Murat and Boz, Cavit and Grand'Maison, Francois and Hamdy, Sherif and Sola, Patrizia and Ferraro, Diana and Grammond, Pierre and Turkoglu, Recai and Buzzard, Katherine and Skibina, Olga and Yamout, Bassem and Altintas, Ayse and Gerlach, Oliver and van Pesch, Vincent and Blanco, Yolanda and Maimone, Davide and Lechner-Scott, Jeannette and Bergamaschi, Roberto and Karabudak, Rana and Iuliano, Gerardo and McGuigan, Chris and Cartechini, Elisabetta and Barnett, Michael and Hughes, Stella and Sa, Maria José and Solaro, Claudio and Kappos, Ludwig and Ramo-Tello, Cristina and Cristiano, Edgardo and Hodgkinson, Suzanne and Spitaleri, Daniele and Soysal, Aysun and Petersen, Thor and Slee, Mark and Butler, Ernest and Granella, Franco and de Gans, Koen and McCombe, Pamela and Ampapa, Radek and Van Wijmeersch, Bart and van der Walt, Anneke and Butzkueven, Helmut and Prevost, Julie},
title = {Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis},
journal = {European Journal of Neurology},
year = {2023},
doi = {10.1111/ene.15706}
}
EUVIMED